Stocksigma LogoStocksigma Logo

Biocon Receives European Commission Marketing Authorization for Pertuzumab Biosimilar Pebrilzo

Biocon Limited announced that the European Commission granted marketing authorization for Pebrilzo, its biosimilar pertuzumab, to treat HER2-positive

Biocon Receives European Commission Marketing Authorization for Pertuzumab Biosimilar Pebrilzo

Biocon Ltd 路 Press Release 路 18 Nov 2026, 2:03 pm

Biocon Receives European Commission Marketing Authorization for Pertuzumab Biosimilar Pebrilzo Biocon Limited announced that the European Commission granted marketing authorization for Pebrilzo, its biosimilar pertuzumab, to treat HER2-positive breast cancer across multiple disease stages in the EU. Pebrilzo is the first biosimilar approved under the European Medicines Agency's new tailored clinical approach, following a positive CHMP opinion on 17th Sep'26 and recent US FDA approval. With this regulatory clearance, pertuzumab becomes Biocon's fifth oncology biosimilar approved in both Europe and the United States, expanding its global biosimilar portfolio.

Original exchange filing (PDF)

More announcements from Biocon Ltd

All Biocon Ltd announcements